Brief: Aclaris Therapeutics Q1 EPS USD -0.15 Vs. IBES Estimate USD -0.16
07/05/2026 11:59
May 07 (Reuters) - Aclaris Therapeutics Q1 revenue USD 1.996 million vs. IBES estimate USD 1.32 million. Q1 net income USD -19.824 million vs. IBES estimate USD -19.6 million
Recent news on Aclaris Therapeutics
See all newsAclaris Therapeutics Q1 net loss widens on higher R&D spending
Brief: Aclaris Therapeutics Q1 EPS USD -0.15 Vs. IBES Estimate USD -0.16
Brief: Aclaris Therapeutics Says Positive Full Top Line Results From Phase 1A Clinical Trial Of ATI-055
Brief: Aclaris Therapeutics Completes Enrollment In Phase 2 Trial Of Bosakitug (Ati-045) In Atopic Dermatitis
Aclaris Q4 loss narrows, but misses analysts' expectations